VAV1 and familial pancreatic carcinoma: Despite these many open questions, the existing data suggest Vav1 as a promising target for drug design, especially blocking its GEF activity, as was recently implied by Razidlo et al., who demonstrated that inhibition of Vav1 by drugs leads to inhibition of pancreatic cancer metastasis [115].